logo
Ottawa weighing plans on AI and copyright as OpenAI fights Ontario court jurisdiction

Ottawa weighing plans on AI and copyright as OpenAI fights Ontario court jurisdiction

Yahoo19-07-2025
OTTAWA — Canada's artificial intelligence minister is keeping a close watch on ongoing court cases in Canada and the U.S. to determine next steps for the government's regulatory approach to AI.
Some AI companies have claimed early wins south of the border and OpenAI is now fighting the jurisdiction of an Ontario court to hear a lawsuit by news publishers.
Evan Solomon's office said in a statement he plans to address copyright "within Canada's broader AI regulatory approach, with a focus on protecting cultural sovereignty and how [creators] factor into this conversation."
But there are no current plans for a stand-alone copyright bill, as Solomon's office is "closely monitoring the ongoing court cases and market developments" to help chart the path forward.
It's unclear how long it will take for those court cases to determine whether artificial intelligence companies can use copyrighted content to train their AI products.
The sole Canadian case to pose the question was launched late last year by a coalition of news publishers, and the Ontario Superior Court is set to hear a jurisdictional challenge in September.
The coalition, which includes The Canadian Press, Torstar, the Globe and Mail, Postmedia and CBC/Radio-Canada, is suing OpenAI for using news content to train its generative artificial intelligence system.
The news publishers argue OpenAI is breaching copyright by scraping large amounts of content from Canadian media, then profiting from the use of that content without permission or compensation.
They said in court filings that OpenAI has "engaged in ongoing, deliberate, and unauthorized misappropriation of [their] valuable news media works."
"Rather than seek to obtain the information legally, OpenAI has elected to brazenly misappropriate the News Media Companies' valuable intellectual property and convert it for its own uses, including commercial uses, without consent or consideration."
OpenAI has denied the allegations, and previously said its models are trained on publicly available data and "grounded in fair use and related international copyright principles."
The company, which is headquartered in San Francisco, is challenging the jurisdiction of the Ontario court to hear the case.
It argued in a court filing it's not located in Ontario and it does not do business in the province.
"There is no real or substantial connection to Ontario as between the defendants and the issues alleged in the statement of claim," the company said.
OpenAI also argued the Copyright Act doesn't apply outside of Canada.
OpenAI is asking the court to seal some documents in the case. The court is scheduled to hold a hearing on the sealing motion on July 30, according to a schedule outlined in court documents.
It asked the court to seal documents containing "commercially sensitive" information, including information about its corporate organization and structure, its web crawling and fetching processes and systems, and its "model training and inference processes, systems, resource allocations and/or cost structures."
"The artificial intelligence industry is highly competitive and developing at a rapid pace. Competitors in this industry are many, and range from large, established technology companies such as Google and Amazon, to smaller startups seeking to establish a foothold in the industry," says an affidavit submitted by the company.
"As recognized leaders in the artificial intelligence industry, competitors and potential competitors to the defendants would benefit from having access to confidential information of the defendants."
A lawyer for the news publishers provided information on the court deadlines but did not provide comment on the case.
Numerous lawsuits dealing with AI systems and copyright are underway in the United States, some dating back to 2023. In late June, AI companies won victories in two of those cases.
In a case launched by a group of authors, including comedian Sarah Silverman, a judge ruled AI systems' use of published work was fair use, and that the authors didn't demonstrate that use would result in market dilution.
But the judge also said his ruling affects only those specific authors — whose lawyers didn't make the right arguments — and does not mean Meta's use of copyrighted material to train its systems was legal. Judge Vince Chhabria noted in his summary judgment that in "the grand scheme of things, the consequences of this ruling are limited."
In a separate U.S. case, a judge ruled that the use by AI company Anthropic of published books without permission to train its systems was fair use. But Judge William Alsup also ruled that Anthropic "had no entitlement to use pirated copies."
Jane Ginsburg, a professor at Columbia University's law school who studies intellectual property and technology, said it would be too simplistic to just look at the cases as complete wins for the AI companies.
"I think both the question of how much weight to give the pirate nature of the sources, and the question of market dilution, are going to be big issues in other cases," Ginsburg said.
This report by The Canadian Press was first published July 19, 2025.
Anja Karadeglija, The Canadian Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada Stands with Ukraine. Now Ukrainians Stand with Canada.
Canada Stands with Ukraine. Now Ukrainians Stand with Canada.

Yahoo

time6 minutes ago

  • Yahoo

Canada Stands with Ukraine. Now Ukrainians Stand with Canada.

Canada-Ukraine Foundation and Ukrainian Canadian Congress donate $100,000 to the Canadian Red Cross in support of the Manitoba and Saskatchewan Wildfires Appeals Photo Credit: Alexis Aubin/Canadian Red Cross TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- In a heartfelt gesture of solidarity and gratitude, the and the Ukrainian Canadian Congress (UCC) announced a $100,000 donation to the Canadian Red Cross to help meet the needs of people impacted by wildfires in Manitoba and Saskatchewan. Since Russia's full-scale invasion in February 2022, Canadians have stood with Ukraine in extraordinary ways. Together, CUF and UCC, through the Ukraine Humanitarian Appeal (UHA), have raised and committed over $95 million in aid, impacting the lives of more than 6 million Ukrainians. Much of that support has come from communities now facing their own crisis. "As wildfires destroy homes, displace families, and blanket communities in smoke, we see firsthand the toll this emergency is taking on Canadians, many of whom stood with Ukrainians when they needed them most," . "This donation is our way of standing with Canadians now." 'We are grateful to the Canada-Ukraine Foundation and the Ukrainian Canadian Congress for their generous support that will benefit people impacted by wildfires in Manitoba and Saskatchewan,' . 'As we continue to respond to one of the worst wildfire seasons in the prairies, the Red Cross is committed to helping people while they are away from home and as they begin to recover.' 'Our hearts go out to our neighbours whose lives and homes are affected by these wildfires,' said Alexandra Chyczij, National President, Ukrainian Canadian Congress. 'The Ukrainian Canadian Congress will do all we can to support these communities during their time of need.' The $100,000 contribution to the Canadian Red Cross will be used for assisting those impacted by the wildfires in Manitoba and Saskatchewan with immediate and ongoing relief. This includes financial assistance, support to evacuees and the communities hosting them, recovery and resilience efforts in response to the wildfires, as well as supporting community preparedness and risk reduction for future all-hazard disaster events within Manitoba and Saskatchewan. United by care and driven by community, CUF and UCC reaffirm their ongoing commitment to the Canadian communities that continue to make their work possible. To donate and learn more about the CUF, please visit Social Media: Instagram: @canadaukrainefoundation Facebook: @cufoundation YouTube: @canada-ukrainefoundation2010 Media Contacts:Zai Karim zai@ - 647-983-6669Shannon Kenney shannon@ - 416-770-0359 About the Canada-Ukraine Foundation Founded in 1995 during the 18th Ukrainian Canadian Congress (UCC), the Canada-Ukraine Foundation (CUF) was established to coordinate, develop, and deliver humanitarian assistance from Canadians to Ukraine. CUF continues to play a vital role as a national charitable foundation, working to monitor, promote, and support humanitarian aid initiatives. Its mission includes evaluating projects, fostering collaboration among aid providers, setting strategic priorities, and ensuring resources are directed where they can have the greatest impact. CUF also serves as a forum for individuals and organizations—across community, private, and public sectors—committed to supporting Ukraine. In addition to its work abroad, CUF also supports related initiatives within Canada. To learn more: About the CUF-UCC Ukraine Humanitarian Appeal A joint initiative of the Canada-Ukraine Foundation (CUF) and the Ukrainian Canadian Congress (UCC), the CUF-UCC Ukraine Humanitarian Appeal (UHA) was launched in January 2022 to coordinate the efficient delivery of humanitarian aid in response to Russia's full-scale invasion of Ukraine. Its efforts focus on supporting displaced persons, medical care, emergency shelter, and food security—both in Ukraine and among those displaced to Europe and Canada. To date, the UHA has delivered over $95 million in aid, helping more than 6 million people. A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Nice Stock Popped Today
Why Nice Stock Popped Today

Yahoo

time6 minutes ago

  • Yahoo

Why Nice Stock Popped Today

Key Points Nice acquired conversational and agentic artificial intelligence specialist Cognigy for $955 million. The two AI leaders combine to form a powerhouse in the customer experience niche. With Nice's AI-related and self-service sales already growing by 39% prior to the deal, the company is launching full-speed ahead into today's most important technology. 10 stocks we like better than Nice › Shares of enterprise software leader Nice (NASDAQ: NICE) rose 6% as of noon ET on Monday, according to data provided by S&P Global Market Intelligence. True to its artificial intelligence (AI) focus, Nice acquired agentic AI specialist Cognigy for $955 million this morning. This acquisition prompted a positive reaction from the market, and I think it is deserved. Nice: AI innovator, not disruptee Back in June, I wrote about Nice as a potential once-in-a-decade opportunity. At the end of the article, I explained, "It'll be of the utmost importance to keep an eye on Nice's AI sales in each quarterly update and ensure the company remains the AI innovator, not the disruptee." Acquiring Cognigy today, Nice reinforced its chances of remaining an AI innovator, rather than a disruptee. By adding Cognigy, Nice added new conversational and agentic capabilities to its customer experience platform, which accounts for 75% of its sales. The Cognigy AI platform offers its services in over 100 languages and serves more than 1,000 brands, including Adidas, Toyota Motor, and Nestle. Despite its start-up nature, Cognigy was already recognized as a leader in conversational AI according to rankings from Gartner Magic Quadrant and Forrester Wave reports. With Nice itself already counting 85 Fortune 100 companies as customers, this union creates an AI powerhouse in the realms of contact centers as a service and customer engagement in general. In the first quarter of this year, Nice grew its AI-related and self-service sales by 39%. Adding Cognigy's AI capabilities, client list, and cross-selling potential should only add fuel to this fire. Even after today's pop, Nice still trades at just 15 times free cash flow. This discounted valuation, paired with Cognigy's addition, keeps Nice a once-in-a-decade opportunity in my eyes. Should you invest $1,000 in Nice right now? Before you buy stock in Nice, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nice wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Josh Kohn-Lindquist has positions in Adidas Ag. The Motley Fool has positions in and recommends Nice. The Motley Fool recommends Gartner and Nestlé. The Motley Fool has a disclosure policy. Why Nice Stock Popped Today was originally published by The Motley Fool Sign in to access your portfolio

Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings

Yahoo

time6 minutes ago

  • Yahoo

Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings

Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store